arrow
Back
A

Ashita Waterston

NHS Greater Glasgow and Clyde

20H-index
57Paper Count
2.0KCitation Count
Published Papers 18
Publication Date
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma
err2025-10-10
err0
errOAAI
errClaire Glen; Stephen J.H. Dobbin; Kenneth Mangion; Alasdair Henderson; Katriona Brooksbank; Caroline J. Coats; Frederick H. Epstein; Peter Kellman; Elaine Butler; Thomas R. Jeffry Evans; Rob Jones; John McClure; Giles Roditi; Yun Yi Tan; Ashita Waterston; Paul Welsh; Mark C. Petrie; Ninian N. Lang
errShare
errSave
Cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma: a prospective study incorporating risk scores, cardiac biomarkers and cardiovascular magnetic resonance imaging
err2024-10-28
err0
PREAI
errGlen, C.; Dobbin, S. J. H.; Mangion, K.; Macdonald, E.; Butler, E.; Brooksbank, K.; Coats, C.; Roditi, G.; Tan, Y. Y.; Waterston, A.; Petrie, M. C.; Lang, N. N.
errShare
errSave
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial
err2024-08-01
err1
PREAI
errGogenur, Mikail; Rosen, Andreas Weinberger; Iveson, Timothy; Kerr, Rachel S.; Saunders, Mark P.; Cassidy, Jim; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; Pearson, Sarah; Boyd, Kathleen A.; Briggs, Andrew H.; Waterston, Ashita; Medley, Louise; Ellis, Richard; Dhadda, Amandeep S.; Harrison, Mark; Falk, Stephen; Rees, Charlotte; Olesen, Rene K.; Propper, David; Bridgewater, John; Azzabi, Ashraf; Cunningham, David; Hickish, Tamas; Gollins, Simon; Wasan, Harpreet S.; Kelly, Caroline; Goegenur, Ismail; Hollaender, Niels Henrik
errShare
errSave
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
err2024-01-01
err1
errOAAI
errDayimu, Alimu; Gupta, Avinash; Matin, Rubeta N.; Nobes, Jenny; Board, Ruth; Payne, Miranda; Rao, Ankit; Fusi, Alberto; Danson, Sarah; Eccles, Bryony; Carser, Judith; Brown, Ciara O'Hanlon; Steven, Neil; Bhattacharyya, Madhumita; Brown, Ewan; Gonzalez, Michael; Highley, Martin; Pickering, Lisa; Kumar, Satish; Waterston, Ashita; Burghel, George; Demain, Leigh; Baker, Eleanor; Wulff, Jerome; Qian, Wendi; Twelves, Sophie; Middleton, Mark; Corrie, Pippa
errShare
errSave
Cardiotoxicity of BRAF/MEK Inhibitors A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores
err2023-10-01
err10
errOAAI
errGlen, Claire; Adam, Sarah; McDowell, Kirsty; Waterston, Ashita; Tan, Yun Yi; Petrie, Mark C.; Coats, Caroline J.; Lang, Ninian N.
errShare
errSave
Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018
err2023-04-11
err0
errOAAI
errClarke, Julie; Bennie, Marion; Kurdi, Amanj; Pan, Jiafeng; Mueller, Tanja; Crearie, Christine; Baillie, Kelly; Laskey, Jennifer; Waterston, Ashita
errShare
errSave
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors JACC: CardioOncology State-of-the-Art Review
err2022-03-01
err30
errOAAI
errGlen, Claire; Tan, Yun Yi; Waterston, Ashita; Evans, Thomas R. Jeffry; Jones, Robert J.; Petrie, Mark C.; Lang, Ninian N.
errShare
errSave
Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer
err2020-09-01
err22
errOAAI
errCameron, Alan C.; McMahon, Kelly; Hall, Mark; Neves, Karla B.; Rios, Francisco J.; Montezano, Augusto C.; Welsh, Paul; Waterston, Ashita; White, Jeff; Mark, Patrick B.; Touyz, Rhian M.; Lang, Ninian N.
errShare
errSave
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
err2019-12-01
err26
errOAAI
errIvesono, Timothy; Boydo, Kathleen A.; Kerro, Rachel S.; Robles-Zuritao, Jose; Saunders, Mark P.; Briggso, Andrew H.; Cassidyo, Jim; Hollandero, Niels Henrik; Taberneroo, Josep; Haydon, Andrew; Glimeliuso, Bengt; Harkino, Andrea; Allano, Karen; McQueeno, John; Pearsono, Sarah; Waterstono, Ashita; Medleyo, Louise; Wilsono, Charles; Elliso, Richard; Essapen, Sharadah; Dhaddao, Amandeep S.; Harrison, Mark; Falko, Stephen; Raoufo, Sherif; Rees, Charlotte; Oleseno, Rene K.; Proppero, David; Bridgewatero, John; Azzabio, Ashraf; Farrugiao, David; Webbo, Andrew; Cunninghamo, David; Hickish, Tamas; Weavero, Andrew; Gollins, Simon; Wasano, Harpreet; Paulo, James
errShare
errSave
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018)
err2019-12-01
err4
errOAAI
errCorrie, P. G.; Marshall, A.; Nathan, P. D.; Lorigan, P.; Gore, M.; Tahir, S.; Faust, G.; Kelly, C. G.; Marples, M.; Danson, S. J.; Marshall, E.; Houston, S. J.; Board, R. E.; Waterston, A. M.; Nobes, J. P.; Harries, M.; Kumar, S.; Goodman, A.; Dalgleish, A.; Martin-Clavijo, A.; Westwell, S.; Casasola, R.; Chao, D.; Maraveyas, A.; Patel, P. M.; Ottensmeier, C. H.; Farrugia, D.; Humphreys, A.; Eccles, B.; Young, G.; Barker, E. O.; Harman, C.; Weiss, M.; Myers, K. A.; Chhabra, A.; Rodwell, S. H.; Dunn, J. A.; Middleton, M. R.
errShare
errSave
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
err2019-11-01
err29
PREAI
errSchadendorf, Dirk; Ascierto, Paolo A.; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen; Maio, Michele; Fierro, Maria Teresa; Hoeller, Christoph; Terheyden, Patrick; Gutzmer, Ralf; Guren, Tormod K.; Bafaloukos, Dimitrios; Rutkowski, Piotr; Plummer, Ruth; Waterston, Ashita; Kaatz, Martin; Mandala, Mario; Marquez-Rodas, Ivan; Munoz-Couselo, Eva; Dummer, Reinhard; Grigoryeva, Elena; Young, Tina C.; Nathan, Paul
errShare
errSave
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
err2019-09-01
err65
errOAAI
errNathan, Paul; Ascierto, Paolo A.; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen; Maio, Michele; Fierro, Maria Teresa; Hoeller, Christoph; Terheyden, Patrick; Gutzmer, Ralf; Guren, Tormod K.; Bafaloukos, Dimitrios; Rutkowski, Piotr; Plummer, Ruth; Waterston, Ashita; Kaatz, Martin; Mandala, Mario; Marquez-Rodas, Ivan; Munoz-Couselo, Eva; Dummer, Reinhard; Grigoryeva, Elena; Young, Tina C.; Schadendorf, Dirk
errShare
errSave
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
err2018-11-13
err18
errOAAI
errRobles-Zurita, Jose; Boyd, Kathleen A.; Briggs, Andrew H.; Iveson, Timothy; Kerr, Rachel S.; Saunders, Mark P.; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Segelov, Eva; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; McQueen, John; Pearson, Sarah; Waterston, Ashita; Medley, Louise; Wilson, Charles; Ellis, Richard; Essapen, Sharadah; Dhadda, Amandeep S.; Hughes, Rob; Falk, Stephen; Raouf, Sherif; Rees, Charlotte; Olesen, Rene K.; Propper, David; Bridgewater, John; Azzabi, Ashraf; Farrugia, David; Webb, Andrew; Cunningham, David; Hickish, Tamas; Weaver, Andrew; Gollins, Simon; Wasan, Harpreet S.; Paul, James
errShare
errSave
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
err2018-08-01
err52
errOAAI
errCorrie, P. G.; Marshall, A.; Nathan, P. D.; Lorigan, P.; Gore, M.; Tahir, S.; Faust, G.; Kelly, C. G.; Marples, M.; Danson, S. J.; Marshall, E.; Houston, S. J.; Board, R. E.; Waterston, A. M.; Nobes, J. P.; Harries, M.; Kumar, S.; Goodman, A.; Dalgleish, A.; Martin-Clavijo, A.; Westwell, S.; Casasola, R.; Chao, D.; Maraveyas, A.; Patel, P. M.; Ottensmeier, C. H.; Farrugia, D.; Humphreys, A.; Eccles, B.; Young, G.; Barker, E. O.; Harman, C.; Weiss, M.; Myers, K. A.; Chhabra, A.; Rodwell, S. H.; Dunn, J. A.; Middleton, M. R.
errShare
errSave
VASCULAR EFFECTS OF ANTI-CANCER CISPLATIN THERAPY
err2018-06-01
err0
PREAI
errCameron, Alan C.; Hall, M.; Rios, F.; Waterston, A.; White, J.; Touyz, R. M.; Lang, N. N.
errShare
errSave
The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer
err2016-11-21
err36
errOAAI
errDreyer, Stephan B.; Powell, Arfon G. M. T.; McSorley, Stephen T.; Waterston, Ashita; Going, James J.; Edwards, Joanne; McMillan, Donald C.; Horgan, Paul G.
errShare
errSave
Translational research with RG7160 (GA201) leads to a phase II clinical study in combination with FOLFIRI in 2nd line metastatic colorectal cancer (mCRC)
err2012-04-01
err0
PREAI
errCervantes, Andres; Markman, Ben; Siena, Salvatore; Pericay, Carles; Aprile, Giuseppe; Bridgewater, John; Cubillo, Antonio; Waterston, Ashita; Paz Ares, Luis; Soria, Jean-Charles; Temam, Stephane; Oppenheim, David; Chick, Jon; Carlile, David; Golding, Sophie; Banholzer, Maria Longauer; Passioukov, Alexandre; Gerdes, Chrstian; Soehrman, Sophia; Mancao, Christoph; Manenti, Luigi; Tabernero, Josep
errShare
errSave